Chimeric proteins that induce effects directed against viruses

Details Chimeric proteins that induce effects directed against viruses Chimeric proteins that induce effects directed against viruses

2011-05-24

2011-05-24

Mosher, Mary E (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S192100, C424S218100, C435S005000, C530S350000

Reexamination Certificate

active

07947281

ABSTRACT:
The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein fromNeisseria meningitidiswith dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.

REFERENCES:
patent: 7279164 (2007-10-01), Hermida Cruz et al.
patent: 2004/0259224 (2004-12-01), Guirakhoo
patent: 0474313 (1992-03-01), None
patent: 1418180 (2004-05-01), None
patent: 1454988 (2004-09-01), None
patent: WO9306214 (1993-04-01), None
patent: WO 96/37221 (1996-11-01), None
patent: WO 97/26359 (1997-07-01), None
patent: WO9743310 (1997-11-01), None
patent: WO9823754 (1998-06-01), None
patent: WO 9831814 (1998-07-01), None
patent: WO9907733 (1999-02-01), None
patent: WO9918216 (1999-04-01), None
patent: WO 00/66791 (2000-11-01), None
patent: WO2004052293 (2004-06-01), None
patent: WO2005002501 (2005-01-01), None
patent: WO2006078657 (2006-07-01), None
patent: WO2006136697 (2006-12-01), None
patent: WO2007124698 (2007-11-01), None
Blok, J., et al., “Variation of the Nucleotide and Encoded Amino Acid Sequences of the Envelope Gene from Eight Dengue-2 Viruses”, Archives of Virology 1989, 105(1-2):39-53.
Lanciotti, Robert S., et al., “Molecular evolution and epidemiology of dengue-3 viruses”, Journal of General Virology 1994, 75(1):65-75.
Lanciotti, Robert S., et al., “Molecular evolution and phylogeny of dengue-4 viruses”, Journal of General Virology 1997, 78(9):2279-2286.
Silva, Ricardo, et al., “Characterisation of the 1pdA gene fromNeisseria meningitidisby polymerase chain reaction, restriction fragment length polymorphism and sequencing”, FEMS Microbiology Letters May 1999, 174 (1):191-199.
Tettelin, Herve, et al., “Complete Genome Sequence ofNeisseria meningitidisSerogroup B Strain MC58”, Science 2000, 287(5459):1809-1815.
Wang, Eryu, et al., “Evolutionary Relationships of Endemic/Epidemic and Sylvatic Dengue Viruses”, Journal of Virology 2000, 74(7):3227-3234.
Chaturvedi et al., “Dengue Vaccines: Problems and Prospects,” Indian J. Med. Res. vol. 121, May 2005, pp. 639-652.
Perez et al., “Safety and Preliminary Immunogenicity of the Recombinant Outer Membrane Protein P64K ofNeiseria meningitisin Human Volunteers,” Biotechnol. Appl. Biochem, 34, 121-125 (2001).
Pugachev et al., “New Developments in Flavivirus Vaccines with Special Attention to Yellow Fever,” Curr Opin Infect Dis 18:387-394 (2005).
Silva et al., “Characterization of the IpdA Gene fromNeisseria meningitidisby Polymerase Chain Reaction, Restriction Fragment Length Polymorphism and Sequencing,” FEMS Microbiology Letters 174 (1999) 191-199.
Srivastava et al., “Mice Immunized with a Dengue Type 2 Virus E and NS1 Fusion Protein Made inEscherichia coliare Protected Against Lethal Dengue Virus Infection,” Vaccine vol. 13, No. 13 (1995).
Database UniProt (online) Subname: Full=Polyprotein; XP002492705 retrieved from EBI accession No. UNIPROT: Q2QFY7 Database accession No. Q2QFY7 the whole document (Jan. 24, 2006).
Shiryaev Sergey A et al., “Cleavage Targets and the D-Arginine-Based Inhibitors of the West Nile Virus NS3 Processing Proteinase”, Biochemical Journal, vol. 393, No. Part 2, 503-511 (2006).
Portal-Nunez S. et al., “Peptide Inhibitors of Hepatitis C Virus NS3 Protease” Antiviral Chemistry & Chemotherapy, Blackwell Scientific Publ. London, GB, vol. 14, No. 5, 225-233 (2003).
Deshayes S. et al., “Cell-Penetrating Peptides: Tools for Intracellular Delivery of Therapeutics”, CMLS Cellular and Molecular Live Sciences, Birkhauser-Verlag, BA, vol. 62, No. 16, 1839-1849 (2005).
Murray, et al., “Processing of the Dengue Virus Type 2 Proteins prM and C-prM”, Journal of General Virology, 74, 175-182 (1993).
Goncalvez et al., “Epitope Determinants of a Chimpanzee Fab Antibody that Efficiently Cross-Neutralizes Dengue Type 1 and Type 2 Viruses Map to Inside and in Close Proximity to Fusion Loop of the Dengue Type 2 Virus Envelope Glycoprotein”, Journal of Virology, 78(23):12919-12928(2004).
Mason et al., “The Antigenic Structure of Dengue Type I Virus Envelope with NS1 Proteins Expressed inEscherichia coli”, Journal of General Virology, 71, 2107-2114(1990).
Mota et al., “Induction of Protective Antibodies Against Dengue Virus by Tetravalent DNA Immunization of Mice with Domain III of the Envelope Protein”, Vaccine 23, 3469-3476(2005).
Database EBI (Online) Envelope Glycoprotein (Fragment) Shu L. and Zuo, L. “No Title” XP002430600 Retrieved from UNIPROT/TREMBL accession No. Q7TLC5, Database accession No. Q7TLC5-Abstract, (2008).
Thullier et al., “A recombinant Fab Neutralizes Dengue Virus in Vitro”, Journal of Biotechnology, Elsevier Science Publishers, vol. 69, No. 2-3, pps. 183-190 (1999) Abstract.
Monath, T. “Dengue and Yellow Fever—Challenges for the Development and Uses of Vaccines”, N. Engl J. Med 357:22 2222-2225 (2007).
Mustafa et al., “Dengue Vaccine The Current Status”, MJAFI, vol. 64, No. 2, 161-164 (2008).
Shresta, et al., “Murine Model for Denjue Virus-Induced Lethal Disease with Increased Vascular Permeability”, Journal of Virology, 80:20, 10208-10217 (2006).
Irie et al., “Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain)”, Gene 75: 197-211 (1989).
Gruenberg et al., “Partial Nucleotide Sequence and Deduced Amino Sequence of the Structural Proteins of Dengue Virus Type 2, New Guinea C and PUO-218 Strains”, J. gen Virol. 69, 1391-1398 (1988).
Zhao et al., “Cloning Full-Length Dengue Type 4 Viral DNA Sequences: Analysis of Genes Coding for Structural Proteins”, Virol. 155:77-88 (1986).
Gaines et al., “Pathogen-Derived Resistance to Dengue Type 2 Virus in Mosquito Cells by Expression of the Premembrane Coding Region of the Viral Genome”, Journal of Virology, p. 2132-2137 (1996).
Kaufman et al., “Monoclonal Antibodies for Dengue Virus PRM Glycoprotein Protect Mice Against Lethal Dengue Infection”, Am. J. Trop. Med. Hyg., 41(5), pp. 576-580 (89-157) 1989.
Bray et al., “Dengue Virus Premembrane and Membrane Proteins Elicit a Protection Immune Response”, Virology, 185, 505-508 (1991).
Randolph et al., “Acidotropic Amines Inhibit Proteolytic Processing of Flavivirus prM Protein”, Virology 174, 450-458 (1990).

Affiliated with

Also associated with

Rating

Chimeric proteins that induce effects directed against viruses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric proteins that induce effects directed against viruses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric proteins that induce effects directed against viruses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2678256